EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amikacin activity against carbapenem-resistant Klebsiella pneumoniae without phenotypic aminoglycoside resistance: impact of aminoglycoside-modifying enzyme (AME) gene aac(6′)-Ib-cr in vitro and in vivo

Jaehoon Kim iD, Jae Eun Seong, Youn-Jung Lee, Sora Park, Min Han, Yongseop Lee, Jung Ah Lee, Jung Ho Kim iD, Jin Young Ahn iD, Su Jin Jeong, Nam Su Ku iD, Joon-Sup Yeom und 2 weitere

JAC-Antimicrobial Resistance · 31.10.2026 · 8 (6)

DOI: 10.1093/jacamr/dlag239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 02.11.2026. Verfasst von Jaehoon Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, R…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Infectious Diseases, National Institute of Health, and Korea Disease Control and Prevention Agency, Department of Internal Medicine, Yonsei University College of Medicine.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Aminoglycosides are often combined with β-lactams for the treatment of carbapenem-resistant Enterobacterales, but the impact of aminoglycoside-modifying enzyme (AME) genes on treatment efficacy in phenotypically susceptible isolates remains unclear. We evaluated whether aac(6′)-Ib-cr, the AME gene with recognized activity against amikacin, attenuates amikacin efficacy in KPC-producing Klebsiella pneumoniae.

Methods

Thirteen clinical isolates of KPC-producing K. pneumoniae without phenotypic aminoglycoside resistance (amikacin MIC ≤4 mg/L; median 2, range 0.5–3 mg/L) were studied. Three were AME-negative; 10 were AME-positive, carrying aac(6′)-Ib-cr, aac(3)-IIa and strA/strB. Amikacin activity was assessed by time-kill assays and a Galleria mellonella survival model, compared with ceftazidime–avibactam.

Results

In time-kill assays, amikacin killing at 24 h was greater in AME-negative isolates than in AME-positive isolates (mean 4.28 ± 1.30 versus 2.41 ± 2.16 log10 cfu/mL), with more regrowth by 72 h in AME-positive isolates (median 1.94 [0–5.82] versus 0 [0–3.32] log10). In the survival model, amikacin reduced larval mortality versus saline (HR, 0.32; 95% CI, 0.24–0.43; P < 0.001). The interaction between AME-positive status and amikacin (HR, 2.11; 95% CI, 1.54–2.90; P < 0.001) indicated reduced efficacy that persisted after adjustment for amikacin MIC (adjusted HR, 2.09; 95% CI, 1.52–2.86; P < 0.001). Ceftazidime–avibactam reduced mortality (HR, 0.24; 95% CI, 0.18–0.33; P < 0.001) with no significant interaction with AME gene status (HR, 1.03; 95% CI, 0.71–1.48; P = 0.894).

Conclusion

Carriage of aac(6′)-Ib-cr was associated with reduced amikacin efficacy despite phenotypic susceptibility, independently of amikacin MIC, consistent with a treatment effect modifier rather than a binary resistance determinant. Genotyping of aac(6′)-Ib-cr may help guide aminoglycoside use in carbapenem-resistant Klebsiella pneumoniae infections.

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
  • Division of Infectious Diseases, Department of Internal Medicine, Seoul Medical Center, 156, Sinnae-ro, Jungnang-gu, Seoul 02053, Republic of Korea.
  • Department of Laboratory Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

ORCID-Profile: Jaehoon Kim, Jung Ho Kim, Jin Young Ahn, Nam Su Ku

Förderung

  • National Institute of Infectious Diseases, National Institute of Health, and Korea Disease Control and Prevention Agency
  • Department of Internal Medicine, Yonsei University College of Medicine

Zitieren

APA

Kim, J., Seong, J. E., Lee, Y. J., Park, S., Han, M., Lee, Y., Lee, J. A., Kim, J. H., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J. S., Lee, H., & Choi, J. Y. (2026). Amikacin activity against carbapenem-resistant Klebsiella pneumoniae without phenotypic aminoglycoside resistance: impact of aminoglycoside-modifying enzyme (AME) gene aac(6′)-Ib-cr in vitro and in vivo. JAC-Antimicrobial Resistance, 8(6). https://doi.org/10.1093/jacamr/dlag239

Vancouver

Kim J, Seong JE, Lee YJ, Park S, Han M, Lee Y, et al. Amikacin activity against carbapenem-resistant Klebsiella pneumoniae without phenotypic aminoglycoside resistance: impact of aminoglycoside-modifying enzyme (AME) gene aac(6′)-Ib-cr in vitro and in vivo. JAC-Antimicrobial Resistance. 2026;8(6). doi:10.1093/jacamr/dlag239

BibTeX
@article{Kim2026,
  author = {Kim, Jaehoon and Seong, Jae Eun and Lee, Youn-Jung and Park, Sora and Han, Min and Lee, Yongseop and Lee, Jung Ah and Kim, Jung Ho and Ahn, Jin Young and Jeong, Su Jin and Ku, Nam Su and Yeom, Joon-Sup and Lee, Hyukmin and Choi, Jun Yong},
  title = {Amikacin activity against carbapenem-resistant Klebsiella pneumoniae without phenotypic aminoglycoside resistance: impact of aminoglycoside-modifying enzyme (AME) gene aac(6′)-Ib-cr in vitro and in vivo},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {6},
  doi = {10.1093/jacamr/dlag239}
}
Kostenlos starten →